Introduction {#s1}
============

Arsenic is a naturally occurring metalloid in the earth's crust, found in water, air, food, and soil ([@c36]). More than 200 million individuals are exposed to arsenic in drinking water, with high prevalence in Taiwan, Bangladesh, India, South America, and the United States ([@c36]). The principal route of arsenic exposure occurs via the ingestion of contaminated drinking water and food, which continues to be a widespread public health concern ([@c4]). Foods that have been reported to have high levels of inorganic arsenic include rice and rice-based products, poultry, apple juice, wine, and beer ([@c10]). Runoff and leaching from rocks, sediment, and anthropogenic sources are significant processes of drinking water contamination ([@c4]). Oral inorganic arsenic exposure has been reported in epidemiological studies to be associated with a wide range of diseases, including cancers of the skin, bladder, lung, kidney, and liver, in addition to developmental, dermatological, neurological, respiratory, immune, cardiovascular, endocrine, and metabolic disorders ([@c36]; [@c52]). Additional studies have been published to further investigate the association between arsenic and type 2 diabetes (T2D) ([@c10]; [@c23]; [@c27]; [@c58]; [@c62]).

Elemental arsenic is present in both inorganic and organic forms and in various oxidative states ([@c36]). Both the pentavalent form, arsenate ($\text{iAs}^{V}$) and the trivalent form, arsenite ($\text{iAs}^{\text{III}}$) have been detected in drinking water ([@c36]). After oral exposure, arsenite metabolism in humans occurs primarily in the liver via arsenic ($+ 3$ oxidation state) methyltransferase (As3MT) and involves sequential reduction and methylation reactions that lead to the formation of both trivalent and pentavalent monomethylated (MMA) and dimethylated (DMA) metabolites ([@c2]). A reductive methylation model has been proposed where trivalent metabolites are conjugated to glutathione (GSH) and ultimately oxidized to pentavalent arsenical metabolites ($\text{MMA}^{V +}$ and $\text{DMA}^{V +}$) as the final products ([@c30]; [@c2]). In recent years, the production of trivalent methylated species has been evaluated and deemed a bioactivation process that increases an individual's susceptibility to arsenic toxicity ([@c2]; [@c4]). Methylarsonous ($\text{MMA}^{\text{III} +}$) and dimethylarsinous acids ($\text{DMA}^{\text{III} +}$) have been found to be cytotoxic ([@c33]) and genotoxic ([@c64]; [@c76]) in both murine and human cell lines.

Studies have attempted to distinguish the risk of arsenic-induced T2D based on exposure level with inconsistent results across experimental models. In 2012, an expert panel assembled by the National Toxicology Program (NTP) deemed evidence for animal research on the topic of arsenic and diabetes inconclusive due to the dissimilarity of animal exposures across studies and to those reported in human exposure studies ([@c49]). The concentration of arsenite in drinking water used in published *in vivo* metabolic studies have ranged from $100\text{ \ ppb}$ up to $50\text{ \ ppm}$ ([@c19]; [@c25]; [@c1]; [@c22]; [@c61]; [@c74]; [@c49]). *In vivo* studies have large discrepancies in exposure duration, concentration, and administration, many of which do not mimic those observed in human populations worldwide ([@c35]; [@c49]; [@c53]; [@c80]). Treatment with arsenite *in vitro* is also highly variable with regard to both dose and duration ([@c49]). In light of these concerns, the expert panel recommended that future arsenic research focus on animal studies designed to mimic internal doses observed in humans, accompanied by low-dose *in vitro* studies on cell lines involved in glucose metabolism ([@c49]; [@c80]).

This review highlights key *in vivo* studies with supporting associations observed *in vitro*. This targeted approach relies on quantitative methodologies to qualitatively synthesize the most relevant studies and address inconsistencies in arsenical species, route of administration, and duration of exposure that are reported in the literature. We provide mechanistic evidence to support epidemiologic findings and advance our understanding of arsenic and T2D development.

Methods {#s2}
=======

Literature Search {#s2.1}
-----------------

We performed a literature review search using PubMed through the Health Assessment Workspace Collaborative (HAWC) Literature Search tool (<https://hawcproject.org/>) to locate studies focusing specifically on arsenite exposure and T2D. Using the HAWC database, we searched PubMed for manuscripts through 17 October 2019, using the following search terms: ("Arsenite" OR "Arsenic" AND "Type 2 Diabetes") OR ("Arsenite" OR "Arsenic" AND "Insulin") OR ("Arsenite" OR "Arsenic" AND "Adipogenesis") OR ("Arsenite" OR "Arsenic" AND "Glucose Transport") OR ("Arsenite" OR "Arsenic" AND "Liver") OR ("Arsenite" OR "Arsenic" AND "Skeletal Muscle") OR ("Arsenite" OR "Arsenic" AND "Pancreatic beta cells") OR ("Arsenite" OR "Arsenic" AND "Chronic"). Both arsenic and arsenite were included as search terms to reduce the possibility of missing a potential manuscript that fulfilled our inclusion criteria. HAWC allows researchers to perform a PubMed database literature search where studies from the results of the query are imported and tagged for either inclusion or exclusion.

Study Selection {#s2.2}
---------------

All studies underwent an identical tagging process and were screened using specified inclusion and exclusion criteria. The inclusion criteria for experimental studies and literature reviews required reporting of both exposure to arsenite and T2D. These criteria were established based on the research question of interest, which focused on the effect of oral arsenite exposure either in mice, rodent or human cell lines relevant to T2D to assess the effect of the chemical on mechanisms involved in dysregulation of glucose homeostasis. The exclusion criteria for experimental studies and literature reviews were that *a*) they were administered a chemical other than the trivalent form of arsenite, *b*) studies were conducted in humans, *c*) studies were "reviews" or "commentaries", *d*) studies with *in utero* exposure only, *e*) studies relied on nonrodent animal models, *f*) included arsenicals as a mixture, or *g*) the assessment of the target organ or cell line was not relevant to glucose homeostasis or T2D development.

Study Characterization {#s2.3}
----------------------

The study tagging was conducted by three researchers (F.C., L.R., and S.D.), and any inconsistencies were resolved by consensus. HAWC was used to manage the study selection process and create a literature Tag-tree that illustrates study identification and classification ([Figure 1](#f1){ref-type="fig"}). We referred to the NTP Office of Health Assessment and Translation (OHAT)'s risk-of-bias rating tool to assess the quality of the animal studies included in this review ([@c55]). A total of 15 animal studies were rated for each of the 9 risk-of-bias questions outlined for animal studies by OHAT's guidelines ([@c55]). The risk-of-bias rating was based on a four-point scale, which included definitively low risk of bias ($+ +$), probably low risk of bias ($+$), probably high risk of bias not reported (−/NR), and definitely high risk of bias (--). Based on our assessment, there is a low probability of risk of bias (Figures S1 and S2).

![Literature Tag-tree illustrating the number of included and excluded studies based on author study characterization. We used relevant medical subject headings (MeSH) terms and targeted searches using PubMed with literature tagging and visualization tools from the Health Assessment Workspace Collaborative (HAWC) Project ([hawcproject.org/](http://hawcproject.org/)).](ehp-128-016001-g001){#f1}

Network Analyses {#s2.4}
----------------

In addition to the literature review, we also relied on chemical- and disease-related gene association data using the publicly available Comparative Toxicogenomics Database (CTD) ([@c50]) to identify genes that are associated with arsenic and T2D ([@c14]). Within CTD, chemicals and diseases are annotated with medical subject headings (MeSH) identifiers that facilitate searching within the database. Our CTD analysis was conducted using MeSH identifiers for sodium arsenite (MeSH:C017947), insulin resistance (MeSH: D007333), and T2D (MeSH: D003924).

To further investigate the biological processes enriched for the list of genes obtained, we used the ClueGO app ([@c9]) within Cytoscape (version summer 2018; Cytospace Consortium) ([@c44]) together with the WikiPathways repository ([@c85]; [@c72]). Cytoscape is able to visualize molecular interaction networks and integrate these with gene expression profiles and other data. Additional features are available as applications. For gene set enrichment analysis (GSEA), we used the WikiPathways repository ([@c85]) containing 418 curated human pathways and 5,866 human genes. Using the ClueGO application within Cytoscape together with GSEA enabled the visualization of nonredundant and highly connected pathways in one functionally grouped network. Pathway selection criteria included a minimum number or percentage of genes (at least three genes or 4% of the total). The selection of highly connected pathways was based on kappa statistics ($\text{kappa\  \ score} > 0.4$). In this way, functionally related biological pathways (containing the same genes) were clustered together.

Results {#s3}
=======

We identified 4,831 manuscripts from a PubMed search in HAWC using MeSH terms related to arsenite and T2D. After exclusion of 4,784 manuscripts, 47 were used in the final review ([Figure 1](#f1){ref-type="fig"}; Excel Table S1, highlighted in red). The included manuscripts were comprised of 15 animal studies and 32 mechanistic studies. Based on our review of the current literature, we propose biological mechanisms to explain the association between arsenic exposure and dysregulation of glucose homeostasis. We further explore and validate published *in vivo* and *in vitro* targets via the use of network analyses from publicly available data. After individual gene lists were obtained, we identified 16 genes commonly affected by sodium arsenite, insulin resistance, and T2D ([Figure 2](#f2){ref-type="fig"}).

![Chemical- and disease-related gene association data. Findings were obtained by searching the publicly available Comparative Toxicogenomics Database (CTD) ([@c50]) using medical subject headings (MeSH) identifiers for sodium arsenite ($\text{iAs}^{{III} +}$) (MeSH:C017947), insulin resistance (MeSH: D007333), and type 2 diabetes (T2D) (MESH: D003924). On the left, a Venn diagram is shown depicting the overlapping genes between the different gene sets. On the right, 16 genes are presented. Venn diagrams were created using Venny (version 2.1; BioinfoGP). Note: CTD_As III, sodium arsenite--associated genes obtained from the CTD; CTD_IR, insulin resistance--associated genes obtained from the CTD; CTD_T2DM, type 2 diabetes mellitus--associated genes obtained from the CTD.](ehp-128-016001-g002){#f2}

Whole-Body Glucose Homeostasis {#s3.1}
------------------------------

Overall, *in vivo* mouse studies show that impaired glucose tolerance has been observed only under exposure to high doses of arsenic, such as $50\text{ \ ppm}$ ([Figure 3](#f3){ref-type="fig"}). [Figure 3](#f3){ref-type="fig"} provides a graphical representation of whole-body glucose homeostasis and insulin resistance observed in the *in vivo* studies reviewed on arsenite exposure. [Figure 3](#f3){ref-type="fig"} reveals that exposure to lower doses of arsenic, such as $4.9\text{ \ ppm}$ and below, does not seem to alter glucose homeostasis in mice unless combined with genetic-induced diabetic models.

![Graphical representation of the direction of the associations between oral exposure to arsenite and (A) insulin resistance, (B) impaired glucose tolerance, (C) organ weight, and (D) body weight, obtained from *in vivo* studies. Note: BW, body weight; GTT, glucose tolerance test; HOMA-IR, homeostatic model assessment for insulin resistance; ITT, insulin tolerance test; WAT, white adipose tissue. Upward-pointing red triangle, significantly higher outcome; downward-pointing blue triangle, significantly lower outcome; black circle, no statistical effect.](ehp-128-016001-g003){#f3}

*In vivo* studies found impaired glucose tolerance in mice treated at high levels (in the range of parts per million) of arsenite. Persistent impaired glucose tolerance was observed in 8-wk-old C57BL/6J male mice based on glucose tolerance tests performed ([@c40]). In two studies by Paul et al. comparing 25- and $50\text{-ppm}$ 8-wk arsenite treatment found that 4-wk-old C57BL/6J male mice developed impaired glucose tolerance only at the highest exposure dose ([@c60], [@c59]). While a relatively lower dose ($3\text{ \ ppm}$) of arsenite treatment for 16 wk did not affect glucose tolerance in 7-wk-old nondiabetic ${C57\text{BLKS}/J}^{\text{db}/m}$ male mice, such treatment increased susceptibility to impaired glucose tolerance in 7-wk-old diabetic ${C57\text{BKS}/\text{Lepr}}^{\text{db}/\text{db}}$ male mice ([@c43]).

Studies in genetic obese ${C57\text{BKS}/\text{Lepr}}^{\text{db}/\text{db}}$ male mice suggest the potential for a synergistic interaction between arsenic exposure and nutritional overload on the development of metabolic disorders. We identified four rodent studies that assessed the effects of arsenic coexposures with a high-fat diet ([@c19]; [@c61]; [@c86]; [@c79]). Swiss Webster mice were treated with arsenic ($100\text{ \ ppb}$) after weaning for 10 wk (to 13 wk of age) ([@c19]). During the course of treatment, a high-fat diet was administered to assess the effects on fatty liver disease. Ectopic fatty lipid deposition and liver damage were observed in these mice ([@c19]). However, despite the induction of hepatic fibrosis, no significant rise in homeostatic model assessment for insulin resistance (HOMA-IR), a measure of insulin resistance, was observed ([Figure 3](#f3){ref-type="fig"}). ([@c19]). However, when mice were exposed to arsenic from embryonic day 5 to 13 wk of age and also fed a high-fat diet after weaning, the effects on hepatic lipid accumulation and fibrosis were even more pronounced, and HOMA-IR was significantly elevated ([@c19]). These findings elucidate important differences for *in utero* vs. postnatal arsenic dosing.

Insulin-Stimulated Glucose Uptake and Glucose Transport {#s3.2}
-------------------------------------------------------

Insulin is an anabolic hormone secreted by pancreatic $\beta\text{ \ cells}$ in response to high blood glucose levels. One of the major functions of insulin is to promote glucose uptake and utilization in peripheral tissues, such as skeletal muscle and white adipose tissue. During insulin resistance, the ability of insulin to promote glucose utilization in skeletal muscle and white adipose tissue is impaired ([@c70]).

Using 3T3-L1 adipocytes as a model, 4 h sodium arsenite treatment at $20\;\mu M$ ($2.6\text{ \ ppm}$) and $100\;\mu M$ ($13\text{ \ ppm}$) decreased insulin-stimulated and basal glucose uptake ([@c83]). At $50\;\mu M$ ($6.5\text{ \ ppm}$) arsenite, 4 h of exposure significantly reduced both insulin-stimulated phosphorylated protein kinase B (AKT) levels and the expression of AKT protein ([@c83]). Similar concentration-dependent effects on insulin-stimulated glucose uptake (ISGU) were observed with the metabolites methylarsine oxide and iododimethylarsine ([@c83]). Notably, the authors did not examine whether $20\;\mu M$ of arsenite treatment for 4 h was sufficient to alter AKT expression. Xue et al. treated 3T3-L1 adipocytes with $0.25–2\;\mu M$ ($32–260\text{ \ ppb}$) arsenite for 7 d ([@c89]). The authors observed decreased insulin-stimulated AKT phosphorylation on serine residue 473, a hallmark of AKT activation. A significant reduction in ISGU was noted at $2\;\mu M$ arsenite treatment, although a decreasing trend in glucose uptake was observed starting at lower concentrations ($0.25–1\;\mu M$) ([@c89]). These responses were correlated to a dose-dependent increase in intracellular GSH and the expression of nuclear factor-erythroid 2-related factor 2 (NRF2), which is a central transcription factor regulating cellular adaptive response to oxidative stress ([@c89]). NRF2 activity was shown to reduce insulin-stimulated AKT phosphorylation and glucose transporter type 4 (GLUT4) translocation in white adipose tissue of leptin deficient $\left( \text{Lep} \right)^{\text{ob}/\text{ob}}$ mice ([@c88]).

Padmaja Divya et al. treated 3T3-L1 preadipocytes and C2C12 myoblasts with 0.5, 1, and $2\;\mu M$ arsenite for 8 wk. At the end of treatment, cells were differentiated to either adipocytes or myotubes ([@c56]). All three concentrations decreased ISGU ([@c56]). While $0.5\;\mu M$ of arsenite showed no significant reduction in the expression of GLUT4 in 3T3-L1 adipocytes or C2C12 myotubes, both 1 and $2\;\mu M$ arsenite decreased GLUT4 expression in these cell lines ([@c56]). Mitochondrial membrane potential was also altered in $2\;\mu M$ arsenite treatment in both 3T3-L1 adipocytes and C2C12 myotubes ([@c56]). This observation coincided with the decreased expression of protein deacetylase sirtuin 3 (SIRT3) and the recruitment of forkhead box O3 (FOXO3A), a transcription factor that regulates reactive oxygen species (ROS) metabolism, to its binding sites in the manganese superoxide dismutase (MnSOD) and peroxisome proliferator-activated receptor-gamma coactivator 1 alpha ($\text{PGC}1\alpha$) genes ([@c77]). Overexpression of SIRT3 and MnSOD in C2C12 myotubes enhanced mitochondrial membrane potential and restored ISGU ([@c56]). Interestingly, SIRT3 appeared to deacetylate FOXO3A, MnSOD, and $\text{PGC}1\alpha$ ([@c56]). Arsenic exposure in C2C12 myoblasts led to the deacetylation of FOXO3A at the lysine 100 residue, which promoted FOXO3A's nuclear localization and subsequent inactivation ([@c56]). These *in vitro* findings elucidated arsenite's role in inhibiting SIRT3--FOXO3A signaling and reducing mitochondrial activity, thereby impairing ISGU ([@c56]).

Arsenite exposure has widespread metabolic effects, also influencing peripheral glucose uptake in the central nervous system ([@c67]). The brain has an obligate glucose requirement and therefore is especially vulnerable to impairments to glucose transporters (GLUT1 and GLUT3) required for glucose to cross the blood--brain barrier and be delivered to neurons ([@c67]). Recent findings reported male C57BL/6J mice exposed to $50\text{ \ ppm}$ for 1 month experienced a decrease in GLUT1 and GLUT3 mRNA levels in the brain, despite a lack of significant change of serum glucose concentrations ([@c67]). Interestingly, arsenite administration significantly increased insulin receptor expression in the hippocampus ([@c67]). However, it is unclear whether the change of glucose tolerance was due to the reduction of GLUT1 and GLUT3 expression in the hippocampus ([@c67]).

A recent study showed impaired brown adipose tissue activity (BAT) in female C57BL/6J mice exposed to 5 or $20\text{ \ ppm}$ arsenic for 17 wk ([@c96]). While these mice experienced no changes in body weight, BAT mass was significantly elevated in the $5\text{-ppm}$ exposure group, with significantly increased adipocyte droplets based on histopathological analysis ([@c96]). Moreover, insulin levels were significantly elevated at both concentrations of exposure, with a significant decrease in genes involved in thermogenesis \[uncoupling protein 1 (UCP1) and $\text{PGC}1\alpha$\] and mitochondrial respiratory chain activity \[Cytochrome C Oxidase Subunit IV (COXIV) and NADH:Ubiquinone Oxidoreductase Subunit S4 (NDUFS4)\] ([@c96]). Another recent study corroborated [@c96]'s findings in male C57BL/6J mice exposed to 5 and $10\text{ \ ppm}$ arsenic for 9 d ([@c5]). Bae et al. ([@c5]) reported arsenic accumulation in BAT, with a significant decrease in lipogenesis, autophagy, and thermogenesis ([@c5]). The authors also found arsenite exposure to impair differentiation of HIB1B brown preadipocytes following a 6-d exposure to arsenite at 2.5-, 5-, and $10\text{-}\mu M$ concentrations ([@c5]). Both *in vivo* and *in vitro*, UCP1, PGC1, peroxisome proliferator--activated receptor gamma ($\text{PPAR}\gamma$), and PR/SET Domain 16 (PRDM16) were all found to be significantly decreased ([@c5]).

Studies focused on arsenic's effects on ISGU have most frequently relied on 3T3-L1 adipocytes to demonstrate impaired effects at both high and low exposures ([Figure 4](#f4){ref-type="fig"}). Skeletal muscle, however, is primarily responsible for the majority of insulin-dependent glucose utilization in the body ([@c16]). The only cell culture model used to study the effects of arsenic on myotubes has been C2C12 myotubes, and arsenite exposure was shown to impair C2C12 differentiation *in vitro* ([@c32]). Future studies should focus on the effects of arsenic on primary myotubes isolated from both rodents and humans. A recent study reported impaired skeletal muscle function, myofiber hypertrophy, mitochondrial myopathy, and altered oxygen consumption after 5 wk of arsenite exposure ($100\text{ \ ppb}$) in 5- to 6-wk-old C57BL/6NTac male mice ([@c3]). While these *in vivo* findings support the evidence found in cultured myotubes (C2C12), additional studies will provide valuable insight regarding arsenic toxicity.

![Graphical representation of the direction of the associations between arsenite treatment and (A) differentiation, (B) oxidative stress and inflammation, (C) glucose-stimulated insulin secretion (GSIS), and (D) insulin-stimulated glucose uptake (ISGU), obtained from *in vitro* studies. Note: AKT, protein kinase B; ASK1, apoptosis signal-regulating kinase 1; C/EBP, CCAAT-enhancer-binding protein $\alpha$ and $\beta$; CHOP10, CCAAT-enhancer-binding protein homologous protein-10; FOXO, forkhead box transcription factor; GLUT, glucose transporter type; G6Pase, glucose 6-phosphatase; NRF2, nuclear factor-erythroid 2-related factor 2; OCR, oxygen consumption rate; PERK, eukaryotic translation initiation factor 2 alpha kinase 3; PPAR, peroxisome proliferator--activated receptor; ROS, reactive oxygen species; SIRT, sirtuin 3. Upward-pointing red triangle, significantly higher outcome; downward-pointing blue triangle, significantly lower outcome; black circle, no statistical effect.](ehp-128-016001-g004){#f4}

The network analyses performed in this review support experimental findings and highlight genes involved in insulin resistance and metabolic disorders. These include insulin, insulin receptor substrate 1 and 2, and heme oxygenase 1 ([Figure 2](#f2){ref-type="fig"}). Arsenic's effects on alterations in gene expression associated with these pathways can have deleterious effects on ISGU and whole-body glucose homeostasis, as demonstrated in [Figures 3](#f3){ref-type="fig"} and [4](#f4){ref-type="fig"}.

Hepatic Glucose Metabolism and Insulin Signaling {#s3.3}
------------------------------------------------

The liver is a key target tissue for arsenic-induced insulin resistance due to its role in both arsenic metabolism and glucose production. Insulin suppresses hepatic gluconeogenesis and glycogenolysis, which are impaired in T2D ([@c6]). Gluconeogenesis is mainly regulated by the modulation of the transcription of rate-controlling enzymes in the pathway, such as phosphoenolpyruvate carboxykinase (PCK1) and the catalytic subunit of glucose 6 phosphatase (G6PC) ([@c65]). Insulin inhibits the transcription of both PCK1 and G6PC. To inhibit glycogenolysis, insulin activates protein phosphatase 1 that inhibits glycogen phosphorylase (GP), which catalyzes the rate-limiting step of glycogenolysis ([@c63]).

Identified studies showed that treating ${C57\text{BLKS}/J}^{\text{db}/m}$ and ${C57\text{BLKS}/J}^{\text{db}/\text{db}}$ male mice with $3\text{ \ ppm}$ arsenite for 16 wk increased PCK1 overexpression ([@c43]). A rise in protein levels of ${Na}^{+}K^{+}\text{-ATPase}$ was observed in the liver of arsenite-treated mice ([@c43]). Arsenite treatment did not affect fasting blood glucose (FBG) levels in ${C57\text{BLKS}/J}^{\text{db}/m}$ mice. However, arsenite treatment elevated fasting glucose levels in ${C57\text{BLKS}/J}^{\text{db}/\text{db}}$ mice ([@c43]). The rates of gluconeogenesis and glycogenolysis were not measured in this study ([@c43]). A similar study in C57BL/6 *db/db* obese mice exposed to $10\text{ \ ppm}$ arsenite for 8 wk found a significant decrease in phosphoenolpyruvate carboxykinase (PEPCK) and G6PC RNA in the livers of exposed mice ([@c42]). Thus, the exact mechanism governing the elevation of FBG is unclear in arsenic-exposed diabetic mice.

A recent study reported a dose-dependent decrease in glycogen content in mouse primary hepatocytes treated with low-dose ($0.5–2\;\mu M$) arsenite for 4 h ([@c94]). Exposure to arsenite resulted in a dose-dependent reduction in insulin-dependent activation of glycogen synthase (GS), the rate-controlling enzyme in glycogenesis, and activation of GP, the rate-controlling enzyme in glycogenolysis ([@c94]). Arsenite treatment for 4 h also inhibited insulin-stimulated AKT phosphorylation at serines 308 and 473, characteristic of AKT activity ([@c94]). In contrast, the activity of glycogen synthase kinase 3, a downstream effector of AKT, was not affected by exposure to arsenite ([@c94]).

The dose and duration of arsenic treatment *in vitro* can be a critical factor in identifying targets of arsenic toxicity relevant to human exposures. A study found that chronic treatment in mice (8 wk) with high arsenite exposure ($150\text{ \ ppm}$) resulted in hepatic damage with observed tissue necrosis and significantly elevated serum glutamate--pyruvate transaminase ([@c54]). HepG2 human hepatoma cells have been used as a model to study both the long- and short-term effects of arsenite on insulin signaling. While a 1-h exposure to arsenite at concentrations up to $1\text{ \ mM}$ did not alter cell viability, the authors observed a decrease in GSH ([@c28]). Conversely, cell viability was greatly reduced after 24 h of arsenite treatment ([@c28]). HepG2 cells treated with 3 or $10\;\mu M$ of arsenite for 24 h attenuated insulin's ability to activate AKT ([@c28]). The phosphorylation of IR by insulin was reduced with exposure to $10\;\mu M$ but not $3\;\mu M$ of arsenite ([@c28]). Similar to findings from murine primary hepatocytes, arsenite treatment did not induce changes in GSK3 activity ([@c28]). The phosphorylation of another insulin-induced downstream effector of AKT, FOXO1, was also not affected by arsenite treatment ([@c28]). Surprisingly, while insulin inhibits the expression of G6PC in healthy individuals ([@c37]), 24 h of arsenite treatment (1, 3, and $10\;\mu M$) also significantly suppressed G6PC expression in Hep2G cells ([@c28]). The combinatorial effect of insulin and arsenite on G6PC expression, however, was not examined. For short-term exposures, HepG2 cells treated with 100 and $300\;\mu M$ of arsenite for 1 h induced both AKT and FOXO1 phosphorylation ([@c28]). Thus, in contrast to the inhibitory effect on insulin action observed after 24 h arsenite treatment, 1 h of arsenite treatment mimicked insulin-like signaling ([@c28]). These findings highlight how the duration of arsenite exposure *in vitro* may have significant implications on our interpretation of epidemiologic findings.

Additional studies assessing arsenic's effects on hepatic glucose regulation are needed. While the current literature is sparse, studies suggest that low-dose arsenite treatment of more than 4 h may alter insulin's anabolic activity in hepatocytes *in vitro*. The network analyses highlight genes involved in hepatic lipid metabolism and inflammation, such as SIRT1 and sterol regulatory element-binding protein (SREBP) ([Figure 5](#f5){ref-type="fig"}). The chemical's pronounced effects on liver function, hepatic steatosis, and injury have also been widely reported in murine models ([@c19]; [@c71]; [@c54]). However, whether arsenic exposure modulates gluconeogenesis and glycogenolysis *in vivo* remains unexplored.

![A network of biological pathways and connected genes that were in common between arsenic ($\text{iAs}3 +$), insulin resistance, and type 2 diabetes (T2D) as found using publicly available gene association data from the Comparative Toxicogenomics Database (CTD). A network of 12 biological pathways and 13 connected genes that were in common between $\text{iAs}3 +$) exposure, insulin resistance (IR), and type 2 diabetes (T2D) as found using publicly available gene association data from the CTD. Gene set enrichment analysis (GSEA) was performed with the Cytoscape app ClueGO using the WikiPathways repository (containing 418 human pathways and 5,866 human genes) ([@c85]). Only pathways containing more than three genes or comprising 4% of the total number of genes in a pathway are depicted in the network. Following GSEA, pathways and genes were assigned to any of the nine summarized phenotypes as described in the paper. The colored pie charts, depicted in the network nodes, represent the different phenotypes associated with that specific pathway or gene. For the label of the gene node, the official HUGO Gene Nomenclature Committee (HGNC)--approved human gene name is used. The label of the pathway node contains the WikiPathway name of the pathway. Note: ADIPOQ, Adiponectin, C1Q And Collagen Domain Containing; EGFR, Epidermal Growth Factor Receptor; INS, Insulin; IRS1, Insulin Receptor Substrate 1; IRS2, Insulin Receptor Substrate 2; LEP, Leptin; LEPR, Leptin Receptor; NOS3, Nitric Oxide Synthase 3; PPARG, Peroxisome Proliferator Activated Receptor Gamma; SIRT1, Sirtuin 1; SLC2A4, Solute Carrier Family 2 Member 4; SOD2, Superoxide Dismutase 2; TNF, Tumor Necrosis Factor.](ehp-128-016001-g005){#f5}

Glucose-Stimulated Insulin Secretion and $\beta\text{-cell}$ Function {#s3.4}
---------------------------------------------------------------------

Pancreatic $\beta\text{ \ cells}$ respond to elevated plasma glucose levels to secrete insulin, which, in turn, stimulates glucose utilization in skeletal muscle and white adipose tissue. This process allows mammals to maintain plasma glucose levels in a narrow range of homeostasis. An identified study showed that treating 8-wk-old C57BL/6J male mice with $50\text{ \ ppm}$ arsenite for 8 wk resulted in impaired glucose tolerance ([@c40]). Whereas no differences in peripheral insulin sensitivity were observed between groups, arsenic-treated mice experienced a reduction in glucose-stimulated insulin secretion (GSIS) compared to controls ([@c40]). High-dose exposure did not affect pancreatic $\beta\text{-cell}$ mass or structure, suggesting that arsenite affects $\beta\text{-cell}$ function ([@c40]). The ability of arsenic to induce ROS and free radicals has been previously reported in human fibroblast cells ([@c34]). The pancreas has low antioxidant capabilities and therefore may be especially vulnerable to arsenic-induced oxidative stress ([@c38]). INS-1832/13 cells treated with low-dose arsenite for 24 h decreased both GSIS and mitochondrial respiration in a dose-dependent manner ([@c21]). Low levels (0.25 and $0.5\;\mu M$) of arsenite treatment for 96 h dampened glucose-induced insulin secretion in INS-1 832/13 rat pancreatic $\beta\text{ \ cells}$ by activating NRF2 activity, which activates the transcription of genes involved in antioxidant defenses. Once activated, these genes decreased endogenous peroxide production necessary for adequate glucose-induced insulin secretion ([@c24]). Arsenite treatment did not affect insulin gene expression in this report, which suggests that the secretion of insulin, but not its synthesis, is the target of arsenic toxicity ([@c24]). Additional studies report similar findings, as arsenic was shown to attenuate GSIS without affecting insulin synthesis in pancreatic islets from mice ([@c20]) and in RINm5F cells ([@c17]) ([Figure 3](#f3){ref-type="fig"}). Another report, however, shows that high levels of sodium arsenite treatment ($5\;\mu M$) for 72 and 144 h in pancreatic $\beta\text{ \ cells}$ isolated from male Wistar rats resulted in significantly lower insulin gene expression (54 and 72%, respectively) ([@c18]). Both dose and duration of treatment requires careful consideration, as $5\;\mu M$ significantly decreased pancreatic $\beta\text{-cell}$ viability after 144 h but not 72 h ([@c18]).

Arsenite may reduce GSIS by interfering with calcium-mediated signaling required for insulin secretory granule exocytosis. Calpains are calcium-sensing proteases that activate proteins such as synaptosome-associated protein 25 (SNAP25), which is involved in insulin secretory vesicle exocytosis ([@c47]). SNAP25 and CALPAIN10 both mediate the fusion of insulin granules with the plasma membrane ([@c47]). While low-dose ($0.5–1\;\mu M$) arsenite treatment of RINm5F rat pancreatic $\beta\text{ \ cells}$ for 72 h did not decrease CAPLAIN10 activity with either basal ($5.6\text{ \ mM}$) or elevated ($15.6\text{ \ mM}$) glucose stimulation, CALPAIN10 activity was significantly increased at $2\;\mu M$ arsenite treatment during both basal and elevated glucose levels ([@c17]). Treatment with $1\;\mu M$ arsenite during insulin-stimulated glucose secretion *in vitro* lowered calpain activity, measured as SNAP-25 proteolysis ([@c17]). While CALPAIN10 activity was significantly increased only after $2\;\mu M$ arsenite treatment, its activity was trending upward starting at $0.5\;\mu M$ ([@c17]). Arsenite concentrations at 1, 2, and $5\;\mu M$ all significantly reduced cell viability ([@c17]).

Endoplasmic reticulum (ER) stress is an additional mechanism involved in impaired GSIS ([@c29]). Sodium arsenite ($4\;\mu M$) treatment in INS-1 cells for 3, 6, 12, and 24 h activated ER stress, as measured by eukaryotic translation initiation factor 2 alpha kinase 3 (PERK) activity ([@c87]). Treating arsenite-treated pancreatic islets with PERK inhibitor restored the capacity of GSIS ([@c87]). This finding suggests arsenite-induced ER stress can suppress GSIS ([Figure 4](#f4){ref-type="fig"}). The induction of ER stress and autophagy is likely to be cell autonomous, as treating INS-1 rat insulinoma cells with arsenite ($4\;\mu M$) for 6 h potentiated PERK activity and altered the expression of autophagy makers ([@c87]).

Oxidative stress induced by arsenite treatment in $\beta\text{ \ cells}$ has been shown to induce apoptosis. INS-1 832/13 pancreatic $\beta\text{ \ cells}$ treated with sodium arsenite ($2.5–10\;\mu M$) exhibited increased intracellular ROS levels and apoptosis ([@c58]). Arsenite exposure also significantly reduced mitochondrial membrane potential and lysosomal membrane composition ([@c58]). Low-dose arsenite ($0.25–1\;\mu M$) exposure in INS-1 832/13 pancreatic $\beta\text{ \ cells}$ for 96 h decreased cell viability and thioredoxin reductase (TRX) activity in a dose-dependent manner ([@c92]). TRX is an enzyme that protects cells from oxidative damage and also associates with and suppresses the activity of apoptosis signal-regulating kinase 1 (ASK1), a protein kinase involved in apoptosis ([@c73]). Indeed, the levels of ASK1 protein were increased in cell culture media upon arsenite treatment ([@c92]). Moreover, reducing ASK1 expression by RNA interference attenuated arsenite-induced cytotoxicity ([@c92]). Thus, arsenic reduced TRX activity, which, in turn, activated ASK1 to induce apoptosis in INS-1 cells. Most significantly, although NRF2 activation reduced GSIS as previously described, NRF2-induced antioxidant response has been shown to be involved in protecting pancreatic $\beta\text{ \ cells}$ from arsenic-induced cellular damage. Both NRF2-knockdown MIN6 pancreatic $\beta\text{ \ cells}$ and pancreatic islets isolated from NRF2-knockout mice experienced increased cytotoxicity upon 2--6 h of arsenite ($2–10\;\mu M$) treatment ([@c91]). MIN6 NRF1 knockdown cells also had decreased antioxidant capabilities ([@c13]). *In vitro* findings showed arsenite treatment decreased cell viability ($1–20\;\mu M$ for 24 h) and enhanced expression of genes involved in arsenic metabolism ([@c13]). These results further corroborate the role of arsenite-induced oxidative stress in pancreatic $\beta\text{-cell}$ apoptosis. HepG2 cells treated with low-dose arsenite ($0.13–2\;\mu M$) for 24 h experienced a significant rise in C-reactive protein (CRP), which is secreted in response to increased inflammation ([@c22]). These experimental findings are consistent with the increased levels of CRP observed in FVB female mice treated with $100\text{ \ ppb}$ arsenite via drinking water for 22 wk ([@c22]). Another study found 16 wk of arsenite ($3\text{ \ ppm}$) exposure increased inflammation, ROS, and vacuole formation in pancreatic islet of db/m mice and further exacerbated these conditions in db/db mice ([@c43]).

*In vivo* studies that assess the effect of arsenic on the pancreas were conducted by exposing rodents at parts-per-million levels for a duration of at least 8 wk. Several of these studies showed that arsenic treatment increased pancreatic damage, which is in agreement with *in vitro* studies that report exposures starting at $1\;\mu M$ to induce apoptosis. Most studies ([@c17]; [@c20]; [@c18]; [@c28]) that treat with arsenic levels $> 1\;\mu M$ report a reduction in GSIS, which supports dose-specific effects on glucose homeostasis ([Figure 4](#f4){ref-type="fig"}). Studies suggest that lower dose and/or shorter exposure duration ([@c24]; [@c92]; [@c87]; [@c58]) have the potential to induce pancreatic $\beta\text{-cell}$ inflammation and decrease pancreatic tissue weight ([@c43]; [@c40]). Discrepancies in experimental findings reported across animal studies may also be due to different susceptibilities across animal strains and species ([@c26]). Several mechanisms were identified as mediating arsenic-induced $\beta\text{-cell}$ apoptosis, including up-regulated oxidative and ER stress ([Figure 4](#f4){ref-type="fig"}). Interestingly, arsenic activation of NRF2 may inhibit endogenous ROS necessary for glucose uptake and insulin secretion ([@c88]). However, the activation of NRF2 was also shown to protect $\beta\text{ \ cells}$ from apoptosis ([@c48]) and therefore has multiple implications in maintaining glucose homeostasis at various arsenic exposure concentrations. The network analyses performed reveal five genes associated with oxidative stress and inflammatory responses, including complement 3 (C3), tumor necrosis factor (TNF), nitric oxide synthase 3 (NOS3), heme oxygenase 1 (HMOX1), and superoxide dismutase 2 (SOD2) ([Figure 5](#f5){ref-type="fig"}). Further investigation of these mechanisms at chronic low doses relevant to human exposures is necessary going forward ([@c31]).

Adipose Tissue Function {#s3.5}
-----------------------

White adipose tissue is the primary organ responsible for the storage of lipids in the form of triglycerides. Increased lipolysis contributes to ectopic lipid deposition in target tissues involved in glucose metabolism, such as the liver and skeletal muscle ([@c69]). Ectopic lipid deposition is one of the major mechanisms of insulin resistance ([@c69]). Thus, both excess storage of lipids in white adipose tissue, such as obesity and lipodystrophy, have significant effects on insulin sensitivity and glucose homeostasis ([@c68]; [@c69]). Adipose tissue is also an endocrine organ that secretes various adipokines to modulate metabolic functions ([@c12]; [@c39]). Both *in vivo* and *in vitro* studies have found arsenic treatment to modulate adipocyte function and differentiation ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}, respectively). Exposure to arsenite (5 or $50\text{ \ ppm}$) in 4-wk-old C57BL/6J male mice for 18 wk significantly decreased serum adiponectin levels ([@c74]), a key adipokine in insulin sensitivity ([@c69]; [@c93]). However, it remains unclear whether the reduction of plasma adiponectin levels contributes to arsenic's effects.

Most of the *in vivo* studies of chronic arsenite exposure found in our search showed no significant differences in weight gain or overall body mass ([Figure 3](#f3){ref-type="fig"}) ([@c1]; [@c3]; [@c40]; [@c74]). Treating 5- to 6-wk-old C57BL/6J male mice with $100\text{ \ ppb}$ arsenite for 5 wk induced lipid mobilization that resulted in elevated ectopic accumulation of lipids in skeletal muscle ([@c25]). Treating adipocytes differentiated from human mesenchymal stem cells (hMSCs) with $1\;\mu M$ arsenite for 72 h increased glycerol release, an indicator of the lipolytic activity in adipocytes ([@c25]). Interestingly, arsenite treatment also resulted in lower expression of PERILIPIN1, a lipid droplet protein found in adipocytes ([@c25]). These responses were reduced by pertussis toxin, an inhibitor of $\text{Gi-}\alpha$ subunit of heterotrimeric G protein. Indeed, antagonizing Gi-coupled endothelin-1 type A receptor attenuated arsenite's lipolytic response, whereas antagonizing endothelin-1 type B receptor decreased the ability of arsenite to suppress PERILIPIN1 expression ([@c25]). These results suggest that arsenic modulates PERILIPIN1 expression and lipolysis through different mechanisms ([Figure 4](#f4){ref-type="fig"}). PERILIPIN1 does, however, play an important role in the regulation of lipolysis in adipocytes ([@c78]). PERILIPIN1 associates with and inhibits adipocyte triglyceride lipase (ATGL), an enzyme that hydrolyzes triacylglycerol to diacylglycerol. Upon the induction of protein kinase A (PKA) signaling by norepinephrine, PERILIPIN1 is phosphorylated by PKA, which prompts its dissociation from ATGL. Phosphorylated PERILIPIN1 subsequently recruits phosphorylated hormone-sensitive lipase, which hydrolyzes diacylglycerol to monoacylglycerol. This process enhances lipolysis in adipocytes. Thus, reducing the expression of PERILIPIN1 will result in the augmentation of basal lipolysis, yet also attenuate norepinephrine- and cyclic adenosine monophosphate cAMP-induced lipolysis.

Adipocyte number (hyperplasia) and size (hypertrophy) are important features of white adipose tissue. Five-week arsenite exposure ($100\text{ \ ppb}$) *in vivo* was shown to reduce adipocyte numbers in white adipose tissue ([@c25]). These results suggest arsenite treatment impairs adipogenesis ([Figure 4](#f4){ref-type="fig"}). Pertussis toxin and antagonists of endothelin-1 type A and B receptors decreased arsenite's ability to inhibit hMSCs differentiation into adipocytes ([@c41]). Moreover, reduced expression of endothelin-1 type A and B receptors in preadipocytes attenuated arsenite-inhibited adipogenesis ([@c41]). These results suggest that the ability of arsenite to inhibit adipogenesis, like its effect on lipolysis, requires, at least in part, endothelin-1 type A and B receptors.

A multitude of studies have observed the suppressive effect of arsenite on adipogenesis ([Figure 4](#f4){ref-type="fig"}) ([@c11]; [@c33]; [@c82]; [@c84]). Arsenite ($0.2–4\;\mu M$) treatment of hMSCs impaired differentiation to adipocytes ([@c90]). Perhaps unsurprisingly, the expression of transcription factors involved in adipogenesis, such as $\text{PPAR}\gamma$ and CCAAT-enhancer binding protein $\alpha$ and $\beta$ ($C/\text{EBP}\alpha$ and $C/\text{EBP}\beta$), were also reduced, whereas the expression of adipogenic inhibitor Wnt family member 3A (Wnt3a) was increased ([@c90]). Arsenite treatment in 3T3-L1 preadipocytes also suppressed differentiation to adipocytes ([@c33]). Arsenite treatment resulted in higher levels of CCAAT-enhancer-binding protein homologous protein-10 (CHOP10), an ER stress response protein involved in the unfolded protein response (UPR) ([@c33]). CHOP10 is a negative regulator of $C/\text{EBP}\beta$, which acts upstream of PPAR actors involved in adipogenesis, such as $\text{PPAR}\gamma$ and $C/\text{EBP}\alpha$, in the transcriptional cascade regulating adipogenesis ([@c33]). C3H 10T1/2 preadipocytes exposed to sodium arsenite ($6\text{ \ mM}$) for 8 wk also experienced altered morphology and impaired differentiation ([@c82]). Arsenite-treated human hMSCs ($1\;\mu M$ for 24 and 48 h) exhibited significantly altered function of noncoding microRNA involved in adipogenesis ([@c8]; [@c66]). Both culture adipocytes and primary hMSCs isolated from mice treated with arsenite *in vivo* ($100–250\text{ \ ppb}$) increased microRNA 29 (miR-29) and cyclin D1 (CCND1) expression, furthering cell growth rather than adipogenic differentiation ([@c8]).

Recent findings suggest low- and moderate-dose arsenite exposure induces lipolysis and impairs adipogenesis ([@c66]). Mechanistic studies indicate a dose-dependent inhibition of adipocyte differentiation, altering critical pro-adipogenic programming ([Figure 4](#f4){ref-type="fig"}). Arsenic's effects in adipose tissue also manifest in increased ectopic lipid deposition in both the liver and skeletal muscle, which could contribute to the development of insulin resistance ([@c66]). Gene lists obtained from our network analyses complement findings in both *in vivo* and *in vitro* studies and support adipose tissue as a target of arsenic toxicity. Many of the genes highlighted in the network analyses ([Figure 5](#f5){ref-type="fig"}) are directly involved in adipogenesis, altered energy storage, adipokine secretion, and ectopic lipid deposition, further supporting the experimental evidence reported. [Figure 5](#f5){ref-type="fig"} lists the pathways related to arsenic-induced insulin resistance and also depicts the interaction network of both these pathways and select genes identified.

Trivalent Arsenical Metabolites: ${DM}A^{{III} +}$ and ${MM}A^{{III} +}$ {#s3.6}
------------------------------------------------------------------------

Since epidemiologic studies have reported the association of arsenic and T2D, the primary focus of laboratory research in the context of diabetes has relied on the parent compound as the chemical of exposure ([@c10]; [@c23]; [@c27]; [@c58]; [@c62]). Recent evidence, however, has shown trivalent arsenical species interfere with metabolic pathways responsible for glucose homeostasis. A dose-dependent decrease in mitochondrial respiration associated with GSIS in INS-1 832/13 pancreatic $\beta\text{ \ cells}$ was observed for both arsenite and $\text{MMA}^{\text{III} +}$ but not for $\text{DMA}^{\text{III} +}$ ([@c21]). $\text{MMA}^{\text{III} +}$ decreased GSIS in INS-1 cells after 24 h exposure at both 0.375 and $0.5\;\mu M$ ([@c21]). There was, however, no significant decrease observed upon 24 h DMA exposure, even at the highest dose ([@c21]). This research highlights key differences in the effects of arsenical species on GSIS, warranting increased laboratory research on this pathway.

Four hours of exposure to arsenite and $\text{MMA}^{\text{III} +}$ concentrations as low as $0.5–2\;\mu M$ decreased glycogen levels in insulin-stimulated primary murine hepatocytes by interfering with rate-limiting glycogenesis genes GS and GP and increasing glucose output ([@c94]). Both arsenite and $\text{MMA}^{\text{III} +}$ down-regulated GS and up-regulated GP, in addition to inhibiting AKT phosphorylation, insulin's regulatory step for glycogen synthesis ([@c94]). This finding parallels results of arsenic-treated adipocytes, with impaired AKT-dependent GLUT4 mobilization in trivalent arsenical-treated 3T3-L1 preadipocytes ([@c83]).

3T3-L1 preadipocytes, adipose-derived stromal vascular fraction cells (ADSVFCs), and human adipose tissue-derived stem cells (hADSCs), treated with low concentrations of $\text{DMA}^{\text{III} +}$ ($\leq 2\;\mu M$) or $\text{MMA}^{\text{III} +}$ ($\leq 1\;\mu M$), all experienced impaired adipogenesis mediated by UPR and ER stress ([@c33]). While arsenite and $\text{MMA}^{\text{III} +}$ interfered with adipogenesis via CHOP10 in the early stages of differentiation, $\text{DMA}^{\text{III} +}$ did not, suggesting its antiadipogenic effects are mediated via a different target ([@c33]). In addition, greater cytotoxicity was observed for both $\text{MMA}^{\text{III} +}$ and $\text{DMA}^{\text{III} +}$ in 3T3-L1 preadipocytes, SVCs, and hADSCs compared to arsenite ([@c33]). Future research should focus on the specific effects of trivalent arsenical metabolites on metabolic pathways to increase our understanding of the diabetogenic potential of arsenic metabolism and its intermediates.

Discussion {#s4}
==========

Our review of the literature on the laboratory research of arsenite exposure and its effects on glucose homeostasis suggests that several mechanisms may be involved, including insulin-stimulated glucose uptake, glucose-stimulated insulin secretion, hepatic glucose metabolism, and adipose and pancreatic $\beta\text{-cell}$ dysfunction. Arsenite has wide physiological effects, affecting multiple metabolic organs involved in glucose homeostasis. Although the effects of arsenic exposure on the integrity and the physiology of various tissues are reported ([Figure 3](#f3){ref-type="fig"}), the molecular mechanisms underlying these findings are mostly unknown. The *in vitro* studies and targets identified via omic databases of publicly available data have the potential to unravel these mechanisms. Different strains of rodents that respond to arsenic differently could also be used. The expert panel assembled by the NTP has therefore encouraged researchers to assess arsenic's metabolic effects in strains susceptible to these metabolic end points ([@c49]).

Current advances in omics technologies have been paralleled with the use of publicly available databases. Together, these tools have the ability to expand our understanding of chemically induced diseases. A recent study on the use of the CTD for the creation of adverse outcome pathways assessed arsenical exposures and dysregulation of glucose homeostasis as one of its primary case studies ([@c15]). This further emphasizes the relevance of elucidating potential mechanisms of action for a relevant topic in the fields of comparative toxicogenomics and environmental epidemiology ([@c15]). We were able to identify 16 genes commonly affected by sodium arsenite, insulin resistance, and T2D. A potential limitation of using specific key terms is the potential of missing relevant genes, exemplified by the hypermethylation of potassium voltage-gated channel subfamily Q member 1 (KCNQ1), a gene involved in insulin secretion that did not appear in our original search. Despite this limitation, MeSH identifiers continue to be widely used based on narrow research criteria.

Evidence from *in vitro* and *in vivo* studies suggest that arsenite interferes with signaling involved in glucose uptake and insulin secretion, down-regulating molecular targets such as AKT and glucose transporters (GLUT1, GLUT3, and GLUT4), and calcium signaling pathways involved in insulin exocytosis and secretion from pancreatic $\beta\text{ \ cells}$, respectively ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}). Arsenite has been shown to interfere with adipogenesis, which has implications for altered energy storage ([@c69]). Hepatic manifestations are also present upon exposure, with the up-regulation of PCK1 and other rate-limiting enzymes of gluconeogenesis ([@c43]). Trivalent methylated arsenical metabolites MMA and DMA share similar effects to their parent compound, interfering with metabolic pathways involved in glucose homeostasis ([@c94]; [@c33]; [@c20]).

![Arsenite impairs insulin-stimulated glucose uptake (ISGU) in adipocytes and myotubes. Arsenite has been shown to down-regulate AKT and glucose transporter translocation to the plasma membrane in both adipocytes and myotubes ([@c83]; [@c89]). Arsenite also up-regulates antioxidant defenses such as NRF2 and GSH, inhibiting endogenous ROS involved in ISGU ([@c89]; [@c88]). *In vitro*, arsenite has been shown to inhibit SIRT3--FOXO3A signaling to reduce mitochondrial activity and impair ISGU ([@c56]). Note: AKT/PKB, protein kinase B; FOXO3A, forkhead box O3; GLUT, glucose transporter type; GSH, glutathione; IR, insulin receptor; IRS1, insulin receptor substrate-1; NRF2, nuclear factor-erythroid 2-related factor 2; PIP3, phosphatidylinositol 3,4,5-triphosphate; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species; SIRT3, sirtuin 3.](ehp-128-016001-g006){#f6}

![Arsenite disrupts glucose-stimulated insulin secretion (GSIS) in pancreatic $\beta\text{ \ cells}$. Arsenite treatment *in vitro* has been reported to decrease calpain activity, measured as SNAP25 proteolysis. SNAP25 and CALPAIN10 are both needed to fuse insulin presecretory granules with the plasma membrane for insulin secretion. At higher doses, arenite has also been shown to increase ER oxidative stress, which can lead to apoptosis of pancreatic $\beta\text{ \ cells}$ due to the tissue's low abundance of antioxidants ([@c87]; [@c57]; [@c92]). Note: ${Ca}^{2 +}$, calcium; ER, endoplasmic reticulum; GLUT, glucose transporters; K, potassium; ROS, reactive oxygen species; SNAP25, synaptosome-associated protein 25.](ehp-128-016001-g007){#f7}

The 16 genes identified in our CTD analysis encode proteins that are involved in glucose homeostasis, oxidative stress, inflammation, lipid metabolism, energy balance, lipid metabolism, and adipogenesis, among other processes. Among the genes identified, insulin, insulin receptor, insulin receptor substrate 1 and 2 (IRS1 and IRS2, respectively), and Solute Carrier Family 2 Member 4 (SLC2A4) (also known as GLUT4) are components of the insulin signaling pathway that regulate glucose utilization in peripheral tissues ([@c69]). Leptin and leptin receptor are components of leptin signaling, which increases satiety and controls energy balance. $\text{PPAR}\gamma$ encodes a nuclear receptor that positively regulates insulin sensitivity ([@c69]). Thiazolidinediones, a class of antidiabetic drugs, act as agonists of $\text{PPAR}\gamma$ ([@c81]). As discussed above, adiponectin (ADIPOQ) encodes a hormone secreted from white adipose tissue that improves insulin sensitivity ([@c69]). An additional five genes (C3, TNF, NOS3, HMOX1, and SOD2) encode proteins involved in the inflammatory response. SOD2 (MnSOD) protein also clears mitochondrial ROS to reduce oxidative stress ([@c56]). Interestingly, this analysis suggests that advanced glycosylated end products bind to their receptors, which can activate inflammatory pathways. Altogether, these genes provide strong evidence to support the association between arsenic dysregulation in various metabolic tissues.

There remains a need to critically determine which *in vitro* and *in vivo* study designs are most relevant to human exposures. The expression of As3MT in different cell lines may vary substantially, impacting the kinetics of arsenite metabolism and its effects in targets involved in glucose homeostasis. The assessment of sodium arsenite metabolism in four animal species, including rat, hamster, guinea pig, and mouse, found mice to be the most appropriate model to evaluate arsenic toxicity ([@c51]). While mice metabolize arsenic more quickly than humans, they have similar distribution parameters ([@c51]). Since arsenic metabolism kinetics differ between animal models and humans, calculations based solely on allometric scaling may not be valid and therefore are usually not reported ([@c75]). The limitation of using mouse models is commonly due to low biological sample availability (e.g., plasma, urine, tissue) due to the animal's small mass ([@c51]). Rats are considered a less appropriate animal model for arsenic metabolism as a proxy for human exposures than other mammalian models ([@c4]; [@c45]; [@c51]). While circulating $\text{DMA}^{\text{III} +}$ inorganic arsenic metabolite is accumulated in erythrocytes in rats, humans experience arsenic retention in epithelial tissues, such as the skin and lung ([@c45]).

Rodents either metabolize arsenic quicker or sequester it in blood cells and thus require concentrations of arsenic above those found in exposed populations to achieve similar internal doses ([@c49]). However, few studies report internal dose calculations, which require comprehensive water consumption estimates ([@c75]). The current literature also includes a broad duration of exposure periods, ranging from a few days to years ([@c49]). Routes of arsenic administration also vary and include oral exposure via drinking water, oral gavage, and intraperitoneal injection ([@c49]). The use of genetic biomarkers and histopathology of select tissues have instead been more widely employed to convey equivalence to arsenic toxicity in humans ([@c75]).

Conclusions {#s5}
===========

While epidemiology studies have linked arsenic exposure to the development of T2D in populations worldwide, the current mechanism by which arsenic contributes to dysregulation of glucose homeostasis remains elusive in humans despite well-established laboratory models. In the last two decades, efforts have focused on assessing arsenic's effects on metabolic target tissues, including the pancreas, adipose, liver, and skeletal muscle. Most *in vivo* studies have relied on rodents, administering higher arsenite concentrations at parts-per-million levels due to the species' accelerated arsenic metabolism compared to humans. Nonetheless, it is critical to model our experimental designs to internal doses that are relevant to human health and exposures. Human exposure assessment is also limited by the measurement of total arsenic concentration, which also includes organic arsenicals that are not considered hazardous to human health and irrelevant to toxicity associated with inorganic arsenic exposures.

Inconsistencies in the literature highlight the need for additional research characterizing the metabolic effects at chronic, low-dose exposures. High-exposure *in vivo* studies have shown that arsenic treatment alone can reduce GSIS ([@c43]; [@c40]; [@c42]). High-exposure *in vivo* studies report arsenic treatment alone to affect glucose homeostasis by damaging the integrity of the pancreas, interfering with GSIS ([@c43]). However, lower-dose arsenite treatment alone has been found to exacerbate genetic and diet-induced insulin resistance and impaired glucose tolerance ([@c43]; [@c19]; [@c61]). *In vitro* studies of pancreatic $\beta\text{ \ cells}$ mostly confirm that high-dose arsenic exposure increases apoptosis, whereas low-dose arsenic inhibits GSIS ([@c58]; [@c46]; [@c17]). Many other *in vitro* results, however, require the corroboration of *in vivo* studies. For example, arsenic has been shown to affect ISGU in adipocytes and myotubes, increasing the breakdown of glycogen in hepatocytes and inhibiting insulin signaling in these cell types ([@c56]). However, the effects of arsenic on peripheral glucose utilization and hepatic glucose production and insulin signaling *in vivo* have not been extensively explored. Another area of increasing interest is the interaction between arsenic and obesity, as an excess body mass index is a causal factor for T2D development. A recent study suggested a synergistic relationship with chronic arsenic exposure and obesity on T2D, with obese individuals being the most susceptible to T2D development ([@c10]).

We used publicly available omics data and performed pathway identification using online tools to validate the relationship between arsenic and T2D, complementing experimental findings. This analysis resulted in the identification of key genes and pathways involved in arsenite-induced insulin. These data-driven approaches can assist researchers to harmonize, summarize, and structure existing mechanistic knowledge underlying arsenite-induced dysregulation of glucose homeostasis. These techniques can identify knowledge gaps and aid in the development of more focused study designs.

Insulin resistance is a chronic condition with epidemic proportions. The increasing prevalence of T2D both domestically and worldwide, in addition to arsenic's widespread exposure, motivates our efforts to determine arsenic's contribution to the etiology of this metabolic disorder ([@c95]). We hope this review will help to inform public health interventions due to the growing burden of T2D and ongoing arsenic exposure in vulnerable communities worldwide.
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